None listed
Conditions
Brief summary
This single-centre before-and-after retrospective cohort study is being conducted to evaluate the dose–exposure relationship of ß-lactam antibiotics administered by continuous infusion in critically ill patients with sepsis. This has been brought about by a change in practice in the administration of beta-lactam antibiotics at our site following the publication of the BLING III multi-centre randomised trial (doi:10.1001/jama.2024.9779). We anticipate 400 patients will be evaluated.
Interventions
This is a a before-and-after retrospective cohort study. We are performing this study to evaluate the dose-exposure relationship of beta-lactam antibiotics when delivered via continuous infusion. The after period, which is from 1st August 2025 to 31st January 2026, represents the continuous infusion period.
After-period patients will be the comparator group in which patients had received continuous intravenous administration of their intravenous beta-lactam antibiotic. Participants would have re
This is a a before-and-after retrospective cohort study. We are performing this study to evaluate the dose-exposure relationship of beta-lactam antibiotics when delivered via continuous infusion. The after period, which is from 1st August 2025 to 31st January 2026, represents the continuous infusion period. After-period patients will be the comparator group in which patients had received continuous intravenous administration of their intravenous beta-lactam antibiotic. Participants would have received the continuous infusion regardless of their involvement in this study because this was a unit-wide practice change. The change in practice related to the publication of a phase III clinical trial called 'BLING III'. We are evaluating the cumulative dose exposure defined as total dose and duration of beta-lactam therapy as administered during the patient's admission to the intensive care unit. We expect to evaluate a total of 400 patients (200 patients per period).
Sponsors
Austin Hospital, Austin Health
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patient has critical illness requiring ICU admission Adult patient aged greater than 18 years of age Patient has a documented site of infection or strong suspicion of infection Patient has been commenced on piperacillin-tazobactam or meropenem to treat a known or suspected infection. Patient is critically unwell, as defined by one or more organ dysfunction.
Exclusion criteria
Patient age is less than 18 years Patient is known or suspected to be pregnant Patient has a known allergy to piperacillin-tazobactam, meropenem or penicillin Admission for palliative care or potential organ donation.
Outcome results
None listed